Bayer Pharma AG / Xarelto®
Xarelto® is approved for the prevention of stroke in patients with atrial fibrillation and for the treatment and prevention of deep vein thrombosis. Xarelto® belongs to a new class of drugs known as “direct oral anticoagulants or DOACs.” Xarelto® is characterized by particularly easy dosing (compared, for example, to the dosage of vitamin K antagonists) and involves taking pills once a day.
Development and implementation of global marketing materials for the digital channels:
- eLearning applications
- including ad hoc services during the congress phases